Adverse Effect Of Valproic Acid Research Articles

Valproate Exposure in ovo Attenuates the Acquisition of Social Preferences of Young Post-hatch Domestic Chicks.

Embryonic exposure to valproic acid (VPA) is known to produce sociability deficits, resembling human autistic phenotypes, in several vertebrate species. Animals living in groups prefer the proximity of peers and have the ability to perceive and to respond to social signals for modifying behavior. Chicks of Galliform birds, known to display early preference behaviors, have been used extensively for adaptive learning studies. Young precocial birds seem to be useful models also for studying the effect of embryonic VPA treatment. Here, domestic chicken eggs were injected with sodium valproate (200 μl of 35 μmol/L solution) or with vehicle (distilled water) on the 14th day of incubation. After hatching, the chicks were tested for one-trial passive avoidance learning at day 1, vocalization due to isolation as a measure of stress level (day 2), approach preference to large versus small groups of age-matched conspecifics (day 5), and to those with normal versus blurred head features (day 7). In addition, we tested the preference of birds to conspecifics reared in group versus those reared in isolation (day 9), as well as the preference of chicks to familiar versus non-familiar conspecifics (day 21). Our findings confirm previous reports concerning an adverse effect of VPA on embryonic development, including a tendency for aborted or delayed hatching and, occasionally, for locomotor disorders in a small percentage of birds (eliminated from later studies). Otherwise, VPA treatment did not impair motor activity or distress level. Memory formation for the aversive stimulus and discrimination of colors were not impaired by VPA treatment either. Innate social predispositions manifested in approach preferences for the larger target group or for the birds with natural facial features remained unaffected by VPA exposure. The most prominent finding was attenuation of social exploration in VPA-exposed birds (expressed as the frequency of positional switches between two stimulus chicks after the first choice), followed by a deficit in the recognition of familiar conspecifics, unfolding at the end of the third week. Social exploration and recognition of familiar individuals are the key elements impaired at this stage. The results underline the importance of early social exploration in ASD.

Renal dysfunction is rare in Fukuyama congenital muscular dystrophy

BackgroundThe leading cause of death in patients with Fukuyama congenital muscular dystrophy (FCMD) is congestive heart failure or respiratory dysfunction, which is same as that in Duchenne muscular dystrophy (DMD). Recent studies reported that renal dysfunction is a common complication and an increasing cause of death in advanced DMD. It can be attributable to circulatory instability or inappropriate use of drugs for treating cardiac dysfunction. MethodsWe retrospectively evaluated renal function in 38 genetically diagnosed patients with FCMD (range, 1.3–32.9 years; mean age, 13.7 ± 6.9 years) using cystatin C. We examined possible relationships of cystatin C with blood natriuretic peptide and creatinine levels along with cardiac echocardiography findings. ResultsTwenty-five patients were treated for cardiac dysfunction. Elevated cystatin C level was detected only in two, who also showed proteinuria, glycosuria, hematuria, and extremely high β2-microglobulin levels on urine tests, and were thus diagnosed with renal tubular cell damage. Because both patients were treated for intractable epilepsy with various antiepileptic drugs, including valproic acid (VPA), and had low serum carnitine levels, renal tubular cell damage was considered as an adverse effect of VPA. Unlike patients with DMD, no patient with FCMD had renal dysfunction. Such a rare occurrence of renal dysfunction can be attributable to mild cardiac dysfunction, short disease duration, and careful and early fluid management. ConclusionRenal dysfunction is rare in patients with FCMD; however, renal tubular cell damage should be ascertained, particularly in those undergoing VPA treatment for epilepsy.

Adverse effect of valproic acid on an in vitro gastrulation model entails activation of retinoic acid signaling

Valproic acid (VPA), an antiepileptic drug, is a teratogen that causes neural tube and axial skeletal defects, although the mechanisms are not fully understood. We previously established a gastrulation model using mouse P19C5 stem cell embryoid bodies (EBs), which exhibits axial patterning and elongation morphogenesis in vitro. Here, we investigated the effects of VPA on the EB axial morphogenesis to gain insights into its teratogenic mechanisms. Axial elongation and patterning of EBs were inhibited by VPA at therapeutic concentrations. VPA elevated expression levels of various developmental regulators, including Cdx1 and Hoxa1, known transcriptional targets of retinoic acid (RA) signaling. Co-treatment of EBs with VPA and BMS493, an RA receptor antagonist, partially rescued axial elongation as well as gene expression profiles. These results suggest that VPA requires active RA signaling to interfere with EB morphogenesis.

Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.

Background:Weight gain is the most frequent adverse effect of valproic acid (VPA) treatment, resulting in poor compliance and many endocrine disturbances. Similarities in the weight change of monozygotic twins receiving VPA strongly suggests that genetic factors are involved in this effect. However, few studies have been conducted to identify the relevant genetic polymorphisms. Additionally, the causal relationship between the VPA concentration and weight gain has been controversial. Thus, we investigated the effects of single nucleotide polymorphisms (SNPs) in several appetite stimulation and energy homeostasis genes and the steady state plasma concentrations (Css) of VPA on the occurrence of weight gain in patients.Methods:A total of 212 epilepsy patients receiving VPA were enrolled. Nineteen SNPs in 11 genes were detected using the Sequenom MassArray iPlex platform, and VPA Css was determined by high-performance liquid chromatography (HPLC).Results:After 6 months of treatment, 20.28% of patients were found to gain a significant amount of weight (weight gained ≥7%). Three SNPs in the leptin receptor (LEPR), ankyrin repeat kinase domain containing 1 (ANKK1), and α catalytic subunit of adenosine monophosphate-activated protein kinase (AMPK) showed significant associations with VPA-induced weight gain (p < 0.001, p = 0.017 and p = 0.020, respectively). After Bonferroni correction for multiple tests, the genotypic association of LEPR rs1137101, the allelic association of LEPR rs1137101, and ANKK1 rs1800497 with weight gain remained significant. However, the VPA Css in patents who gained weight were not significantly different from those who did not gain weight (p = 0.121).Conclusions: LEPR and ANKK1 genetic polymorphisms may have value in predicting VPA-induced weight gain.

G.P.317: Renal dysfunction in patients with Fukuyama congenital muscular dystrophy

Fukuyama congenital muscular dystrophy (FCMD), characterized by intellectual deficits and epilepsy with cortical migration defects, is the most common congenital muscular dystrophy in Japan. Most patients die of congestive heart failure or respiratory dysfunction, as in Duchenne muscular dystrophy (DMD), in the second decade of life. Recent studies have found that renal dysfunction is a common complication of advanced DMD and is the third leading cause of death in these patients. Circulatory instability caused by cardiac dysfunction is thought to result in renal dysfunction, especially prerenal failure. We retrospectively evaluated renal function in 37 genetically diagnosed FCMD patients (1.3–32.9 years, mean age 13.7 ± 6.9 years) using Cystatin C. We examined possible relationships of Cystatin with the levels of blood natriuretic peptide and creatinine, as well as the cardiac echo results. Twenty-four patients were treated for cardiac dysfunction, but elevated Cystatin C was detected in only two. These two patients also showed proteinuria, glycosuria, hematuria and extremely high levels of β2-microglobulin on urine tests and were thus diagnosed as having kidney tubule cell damage. Since both patients were treated for intractable epilepsy with many types of antiepileptic drugs, including valproic acid (VPA), and had low serum carnitine levels, kidney tubule cell damage was thought to be an adverse effect of VPA. One patient improved in response to a reduced VPA dose, but the other developed Fanconi syndrome. Unlike DMD patients, none of our FCMD patients progressed to prerenal failure. Though FCMD patients also have cardiac dysfunction, careful fluid management is instituted early because dysphagia emerges in the early stage. In DMD patients, inadequate fluid management may also cause circulatory instability, which can progress to prerenal failure. On the other hand, kidney tubule cell damage should be noted in FCMD patients especially with VPA treatment for epilepsy.

Fanconi Syndrome Caused by Valproic Acid

Two severely disabled children with epilepsy, a 6-year-old boy and a 15-year-old girl, had been treated with valproic acid from the ages of 5 and 6 months, respectively, and developed Fanconi syndrome. Both patients were bedridden and fed by means of a nasogastric or gastrostomy tube. Because their Fanconi syndrome appeared to be caused by valproic acid, that treatment was stopped; for both patients, the Fanconi syndrome then resolved, in 6 months and 3 months, respectively. Severely handicapped children may be at risk for valproic acid-induced renal involvement. Although renal involvement is an uncommon adverse effect of valproic acid, Fanconi syndrome due to valproic acid therapy has rarely been reported. In the few previous cases, the patients, who were bedridden and fed through a nasogastric or a gastrostomy tube, had taken valproic acid for an average of approximately 7 years. Nonetheless, their valproic acid blood levels were normal. Urinary abnormalities disappeared in an average of 4 months, as also in the present two cases. The potential for Fanconi syndrome must be considered in children with epilepsy who are treated with valproic acid, especially in severely disabled children.

バルプロ酸服用中のてんかん患者における高アンモニア血症発生リスクに関する症例対照研究

Hyperammonemia is an adverse effect of valproic acid,though it is rarely associated with fatal encephalopathy or disturbance of consciousness.The purpose of this study was to investigate the clinical risk factors for hyperammonemia in patients with epilepsy undergoing valproic acid therapy.To do this,we conducted a survey retrospectively from January 2006 to June 2008.We also performed a case-control study in which blood ammonia levels and other data were measured in inpatients and outpatients,defining hyperammonemia as a blood ammonia level exceeding 200μg/dL.There were 90 cases and 450 controls.Multiple logistic regression analysis was also performed to investigate the risk factors for hyperammonemia,using the cases as a criterion variable.The explanatory variables were factors that showed significance (P<0.05)in univariate analysis.According to multiple regression analysis,risk factors for hyperammonemia were phenytoin coadministration (odds ratio (OR),5.89;95% confidence interval (CI),3.41 to 10.2;p<0.001),phenobarbital coadministration (OR,2.30;95% CI,1.28 to 4.11;p=0.005),and dose of valproic acid (per mg/kg/day,OR,1.05;95% CI,1.02 to 1.07;p<0.001).However,slow-release valproic acid formulations reduced the risk of hyperammonemia (OR,0.51;95% CI,0.30 to 0.85;p= 0.010).In conclusion,identification of risk factors for hyperammonemia due to valproic acid in epileptic patients can help minimize adverse effects.

Localized morphea: a rare adverse effect of valproic acid

Morphea, a specific type of cutaneous sclerosis, is known in the pediatric age group, but not as an adverse effect to the antiepileptic valproic acid. We report a 14-year-old male patient with absence seizures who, after treatment with valproic acid, developed skin tightness on the fingers. A biopsy specimen revealed dermal sclerosis consistent with morphea. His symptoms resolved gradually after discontinuation of the medication. To our knowledge, this is the first patient reported to have an apparently valproic acid–induced localized morphea.

Reversible altered consciousness with brain atrophy caused by valproic acid

A 5-year-old female developed alteration of consciousness during 3 days of long-term treatment with valproic acid for localization-related epilepsy. Computed tomography revealed cerebral atrophy, and electroencephalography presented slow background activity. Consciousness cleared only 12 hours after valproic acid was discontinued, and normal electroencephalography results were evident 1 week later. Cerebral atrophy was nonexistent 2 months later. This rapidly developing but reversible alteration of consciousness in parallel with brain atrophy is recognized as a rare idiosyncratic adverse effect of valproic acid.

La craniosténose de la métopique, effet probable de l’exposition intra-utérine à un traitement maternel par le valproate

Metopic craniosynostosis may be an adverse effect of valproic acid exposed fetus. Cases.– We report two infants with metopic craniosynostosis, born to mothers who were treated with valproic acid. In one case, a prenatal diagnosis was made. In the other case, only the male dizygotic twin was affected. Conclusion. – Trigonocephaly may be a symptom of valproate embryofoetopathy detectable by antenatal ultrasound examination.